By Adriano Marchese
AnaptysBio shares plummeted in premarket trading Wednesday after the company said it will discontinue its dermatitis treatment after the drug failed to meet its targets in recent trials.
Shares fell over 39% to $14 ahead of the morning bell.
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, often referred to as eczema.
Atopic dermatitis is a chronic disease that causes inflammation and irritation of the skin, often beginning at a young age.
"While ANB032 was safe and well tolerated, we're disappointed by these efficacy results in AD and will discontinue further investment in this asset," Chief Executive Daniel Faga said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 11, 2024 09:36 ET (14:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。